-
15194-1A competitive inhibitor of nucleotide binding by Ras-related GTPases binds Rab7 (Ki = 13 nM), preventing BODIPY-linked GTP and GDP binding with EC<sub>50</sub> values of 11.2 and 21 nM, respectively.
-
15194-10A competitive inhibitor of nucleotide binding by Ras-related GTPases binds Rab7 (Ki = 13 nM), preventing BODIPY-linked GTP and GDP binding with EC<sub>50</sub> values of 11.2 and 21 nM, respectively.
-
15194-25A competitive inhibitor of nucleotide binding by Ras-related GTPases binds Rab7 (Ki = 13 nM), preventing BODIPY-linked GTP and GDP binding with EC<sub>50</sub> values of 11.2 and 21 nM, respectively.
-
15194-5A competitive inhibitor of nucleotide binding by Ras-related GTPases binds Rab7 (Ki = 13 nM), preventing BODIPY-linked GTP and GDP binding with EC<sub>50</sub> values of 11.2 and 21 nM, respectively.
-
15317-10An inhibitor of all three PKD isoforms (IC<sub>50</sub>s = 3.2, 0.
-
15317-25An inhibitor of all three PKD isoforms (IC<sub>50</sub>s = 3.2, 0.
-
15317-5An inhibitor of all three PKD isoforms (IC<sub>50</sub>s = 3.2, 0.
-
12046-10A reversible, competitive antagonist of GPR35, blocking activation by the synthetic agonist pamoic acid with a Ki of 12.8 nM less potently blocks activation of GPR35 by zaprinast (IC50 = 160 nM) shows ~57-fold selectivity for GPR35 over the
-
12046-25A reversible, competitive antagonist of GPR35, blocking activation by the synthetic agonist pamoic acid with a Ki of 12.8 nM less potently blocks activation of GPR35 by zaprinast (IC50 = 160 nM) shows ~57-fold selectivity for GPR35 over the
-
12046-5A reversible, competitive antagonist of GPR35, blocking activation by the synthetic agonist pamoic acid with a Ki of 12.8 nM less potently blocks activation of GPR35 by zaprinast (IC50 = 160 nM) shows ~57-fold selectivity for GPR35 over the
-
12046-50A reversible, competitive antagonist of GPR35, blocking activation by the synthetic agonist pamoic acid with a Ki of 12.8 nM less potently blocks activation of GPR35 by zaprinast (IC50 = 160 nM) shows ~57-fold selectivity for GPR35 over the
-
14122-1A selective inhibitor of PKC-induced NF-&kappaB pathway activation (IC<sub>50</sub> = 0.07 &muM) inhibits IL-8 production in HEK293 cells (IC<sub>50</sub> &le 0.